No profile data available.
Aurinia Pharmaceuticals Inc. (AUPH) is a healthcare company in the autoimmune treatment pharmaceuticals industry, based in Edmonton, Canada, with about 128 full-time employees.
It reported revenue of $283.06 million for fiscal year 2025, up 20.4% from fiscal year 2024, and net income of $287.20 million. In Q1 2026 (the quarter ended March 31, 2026) revenue was $77.71 million, up 24.4% from a year before. United States was its largest region in fiscal year 2025, with 93% of revenue. Its market capitalization was $2.22 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis.
Aurinia Pharmaceuticals reported $283.06 million in revenue for fiscal year 2025, up 20.4% from $235.13 million in fiscal year 2024. In Q1 2026 revenue was $77.71 million.
United States: 93% of revenue by region in fiscal year 2025, followed by Japan (7%).
$2.22 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (autoimmune treatment pharmaceuticals) include TG Therapeutics, Inc. (TGTX), Immunovant, Inc. (IMVT), Kiniksa Pharmaceuticals International, plc (KNSA), Viridian Therapeutics, Inc. (VRDN).